Passage Bio Partners with InformedDNA® to Offer Genetic Counseling and Testing for Patients with Frontotemporal Dementia (FTD), a Form of Early Onset Dementia
May 03, 2021 07:00 ET
|
Passage Bio
No-cost genetic screening and counseling program aimed at identifying FTD patients who have certain inherited genetic mutations to guide early treatment intervention and awareness of clinical...
Passage Bio to Report First Quarter 2021 Financial Results on May 5, 2021
April 29, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease
April 05, 2021 07:00 ET
|
Passage Bio
- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options - Urgency for effective treatment underscored by European Commission designation for...
Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
April 01, 2021 07:00 ET
|
Passage Bio
– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company – PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq:...
Passage Bio to Participate in Upcoming April Investor Conferences
March 25, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Appoints Eliseo O. Salinas, M.D., MSc, as Chief Research & Development Officer
March 22, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous...
U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders
March 08, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, March 08, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
March 03, 2021 07:00 ET
|
Passage Bio
- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for...
Passage Bio to Participate in Upcoming March Investor Conferences
March 02, 2021 16:01 ET
|
Passage Bio
PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021
February 24, 2021 07:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...